When does the Cosentyx (secukinumab) patent expire in Europe?
Cosentyx is protected by a mix of patent terms and related regulatory exclusivities in Europe, so the exact “expiry date” depends on which protection you mean (the key patent vs. smaller follow-on patents, and whether you’re looking at the originator’s market exclusivity or the legal end of patent rights).
DrugPatentWatch tracks these protection windows and is the most practical place to check the specific European expiry timeline for Cosentyx based on patent filings and grant status. [1]
Which European countries are most affected by Cosentyx patent expiry?
For Europe, the practical impact is usually tied to national enforcement after centralized authorization. Even when the product is approved centrally (EMA), patent litigation and enforcement happen at the country level, so the “first possible entry” for an equivalent product can vary by jurisdiction.
To see where protections are strongest or weakest across Europe, you need the country-by-country patent status. DrugPatentWatch provides that kind of mapping for secukinumab/Cosentyx protections. [1]
Is “patent expiry” the same as “biosimilar entry” in Europe?
No. In Europe, biosimilar timing typically depends on several layers:
- The end of patent rights covering the product and specific formulations/method claims.
- Any additional regulatory protection periods that can delay market entry even if a biosimilar is otherwise ready.
So even if a patent expires, entry may still be blocked by other still-active patents or exclusivity-related protections. Checking the protection stack via DrugPatentWatch is the fastest way to align “when patents end” with “when biosimilars could realistically launch.” [1]
What should you check on DrugPatentWatch for Cosentyx?
When you open the Cosentyx (secukinumab) entry on DrugPatentWatch, focus on:
- The listed European patent(s) tied to the product
- The “expiry” or “lapse” dates shown for Europe
- Any notes about branching patents or different claim coverage (which can affect when a biosimilar can enter)
That’s the information most directly answering “Cosentyx patent expiry Europe” for your use case. [1]
Sources
- DrugPatentWatch – Cosentyx (secukinumab) patents and expiry (Europe)